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Venous thromboembolism (VTE) encompasses deep vein throm-
bosis (DVT) and its associated complications, which includes pul-
monary embolism (PE), when a thrombus embolizes from its initial 
venous location to the lungs, and also postthrombotic syndrome 
(PTS) when the vein wall becomes fibrosed during the course of 
thrombus resolution. VTE is one of the leading causes of mortality 
and morbidity worldwide. Globally, there are 10 million people per 
year diagnosed with VTE and it is the third leading cardiovascular 
disease after myocardial infarction and stroke.1 Notably, while other 
cardiovascular diseases have been on the decline, the incidence 
of DVT is still increasing.2 In the United States, the management 
of VTE-related events cost an estimated $7 to $10 billion per year 
for 375 000 to 425 000 newly diagnosed patients, whereas in the 
United Kingdom, it represents £640 million per year for ∼100 000 
patients.3,4 Anticoagulants remain the treatment of choice in DVT 
to limit thrombus extension and prevent its recurrence. Whereas 
they have contributed to improved outcomes for DVT patients, they 
also incur elevated bleeding risk, and particularly in cases when the 
thrombus has reached an appreciable size, they have limited efficacy 
while still increasing the bleeding risk.5,6 Between 20% and 50% of 
patients diagnosed with DVT develop PTS long-term sequelae such 
as leg pain, swelling, cramps, itching, and ulcers for the most severe 
cases (5%-10%).7 There is currently no treatment fully alleviating 
these symptoms, although evidence suggests direct oral anticoag-
ulants, in particular rivaroxaban, reduce incidence of PTS compared 
with vitamin K antagonists.7,8 Therefore, identifying novel strategies 
to specifically target PTS after DVT are certainly warranted.
The formation of a pathological thrombus and its resolution 
in DVT can be defined by three main stages. The initiation of a 
venous thrombus usually starts in the valve pockets of the large 
veins and involves the combination of different factors including 
alteration and/or reduction in blood flow that may trigger local 
hypoxia, endothelial cell dysfunction, and elevated hypercoagula-
bility.9,10 Within the first week (stage 1), the thrombus is composed 
mostly of red blood cells with few other cells, including platelets. 
At this stage, the thrombus is firmly attached to a small area at 
the vessel wall initiation site. Progressively, fibrin becomes more 
prominent within the thrombus with evidence of immune cells 
infiltration and endothelial cells covering partially the thrombus 
(stage 2 to ~7 weeks). After a year (stage 3), the remaining tissue 
contains mostly collagen produced by invading fibroblasts with 
few leukocytes.11 The mechanisms that drive thrombus resolution 
are not fully understood but involves various inflammatory cells 
including neutrophils, macrophages, and T cells, but also endo-
thelial cells that drive fibrinolysis, collagenolysis, and neovascu-
larization.5 Importantly, thrombus maturation and restoration of 
vessel patency often goes hand in hand with vessel wall fibrosis 
and intimal thickening. Poor thrombus resolution is one of the 
strongest predictors of PTS, whereas venous hypertension caused 
by venous reflux also contributes to PTS symptoms.6,7,12 Murine 
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models of thrombosis have been invaluable for our understand-
ing of DVT as such studies are generally not possible in human 
DVT patients. Although the complete ligation of the inferior vena 
cava (IVC) offers reproducible thrombus in size, the partial ligation 
model is thought to more closely resemble the human scenario 
where perturbation of blood flow in the venous valves pockets 
plays a crucial role in DVT initiation.13 Importantly, mouse thrombi 
in the stenosis IVC model are remarkably similar histologically to 
thrombi extracted from human DVT patients.14
The role of platelets in early events of DVT have been estab-
lished. Indeed, depletion of platelets in mice led to protection in the 
IVC stenosis model.14 Platelets are thought to facilitate leukocyte re-
cruitment in particular neutrophils are one of the first cells present 
at the site of injury.14 The importance of the von Willebrand factor 
A1-GPIbα axis in DVT has been demonstrated by various studies 
showing that inhibiting that interaction provide protection in this 
model.14-18 Disrupting that interaction was also accompanied with 
a greatly diminished number of leukocytes recruited at the site of 
stenosis.14,15 More recently, von Willebrand factor-primed platelets 
have been shown to interact with neutrophils via SLC44A2,19 one of 
two susceptibility loci recently identified for VTE by genome wide 
association studies.20,21 Additional roles for platelets in DVT have 
been highlighted during the propagation of the thrombus in DVT via 
P-selectin and HMBG1 released from activated platelets, which pro-
motes leukocyte recruitment, activation, and subsequent NET forma-
tion.14,22-25 In this issue of the Journal of Thrombosis and Haemostasis, 
DeRoo et al explored the role of platelets in later stages of DVT. Their 
results are exciting and uncover a novel role for platelets in thrombus 
maturation, fibrosis, and remodeling of the injured vein.
In this study, the authors used the stenosis model of the IVC 
to evaluate the role of platelets in later stages of venous throm-
bosis. First, they established at which time point postsurgery 
thrombus formation, resolution, and vein wall remodeling oc-
curs. Thrombus length and volume gradually decreased from 2 to 
16 days. However, there was no difference between days 8 and 
2, suggesting that thrombus resolution was limited. Thrombus 
fibrosis measured as collagen content was significantly present 
2 weeks postsurgery, whereas fibrosis in the vein was already evi-
dent after a week. These timings are in line with those of the stasis 
model in which maximal thrombus formation has been reported to 
be reached around 2 to 4 days and thrombus resolution initiated 
around 2 weeks postinduction.5,26 To evaluate the role of plate-
lets in thrombus resolution and later stages of DVT, the authors 
therefore chose to deplete platelets in mice subjected to partial 
ligation of the IVC 2 days postsurgery, after the formation of a 
sizable thrombus. Although the reduction in platelet counts did 
not affect the size or length of the thrombus 10 days after IVC ste-
nosis, it had an appreciable effect in the thrombus and vessel wall 
architecture. Indeed, collagen content was reduced by ~50% in 
the thrombus of mice injected with platelet-depleting anti-GPIbα 
antibodies compared with control mice. In addition to diminished 
thrombus fibrosis in these mice, a significant decrease in smooth 
muscle cell invasion was also detected in their thrombi. Another 
important finding from this study by DeRoo et al is that a signifi-
cant reduction in the intimal thickening of platelet-depleted com-
pared with control mice was observed, suggesting platelets not 
only influence thrombus maturation and resolution but also vein 
wall remodeling. The authors speculate that platelets influence 
these processes via molecules such as TGF-β, bFGF, or PDGF that 
are released upon platelet activation.
These results could have potentially important clinical impli-
cations because it is known that as venous thrombi progress into 
resolution stages and fibrosis increases, they are generally more 
resistant to pharmacological therapy.26 As mentioned previously, 
slower thrombus resolution and recanalization combined with 
vein wall thickening are associated with development of PTS.26,27 
Targeting platelets after DVT onset may therefore facilitate throm-
bus resolution without posing the risk of subsequent excessive vein 
wall remodeling. Importantly, thrombi analyzed at day 10 postste-
nosis were significantly smaller than at day 2, indicative that throm-
bus resolution was initiated in platelet-depleted mice as seen for 
control mice. As stated by the authors, however, this time point rep-
resents one of the limitations of the study because thrombus reso-
lution was likely not complete as the thrombus length and volume at 
day 16 were 3.2 mm and 3.4 mm3, respectively, and at day 10 were 
estimated to be 7.4 mm and 13.1 mm3 (similar to those found at 
day 8 for the control mice). Based on the very promising results ob-
tained at day 10, further evaluation of the therapeutic value to tar-
get platelets after thrombus formation in the DVT stenosis model at 
a later timepoint is warranted. Perhaps defining the mechanism by 
which platelet depletion decreases thrombus fibrosis, smooth mus-
cle cell invasion, and vein wall thickening should be established first 
so that one is not limited by the immune response associated with 
administration of antibodies for efficient platelet depletion.
Anucleated platelets continue to amaze us by their multifac-
eted functions. They are increasingly recognized as immune cells 
that orchestrate various inflammatory conditions or fight infec-
tions. Although their role in thrombosis had been more tradition-
ally associated with the arterial system, it is becoming clear that 
they also play a key role in venous thrombosis. Although we are a 
long way away from fully understanding exactly how platelets con-
tribute to later stages of DVT, the manuscript by DeRoo et al pro-
vides exciting perspectives on developing new therapeutic options 
to prevent PTS during the thrombus resolution phase in DVT.
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